Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status:
Completed
Trial end date:
2018-01-22
Target enrollment:
Participant gender:
Summary
RATIONALE: The MAP.3 study was designed to test whether hormone therapy using exemestane may
prevent breast cancer by blocking the production of estrogen.
PURPOSE: The study protocol was amended in May 2011 and the current purpose of the study is
to allow all study participants the opportunity to complete 5 years of exemestane.
Phase:
Phase 3
Details
Lead Sponsor:
NCIC Clinical Trials Group
Collaborators:
Grupo Espanol de Investigacion del Cancer de Mama UNICANCER